MA45377A - Composés hétérocycliques en tant qu'agents antibacteriens - Google Patents

Composés hétérocycliques en tant qu'agents antibacteriens

Info

Publication number
MA45377A
MA45377A MA045377A MA45377A MA45377A MA 45377 A MA45377 A MA 45377A MA 045377 A MA045377 A MA 045377A MA 45377 A MA45377 A MA 45377A MA 45377 A MA45377 A MA 45377A
Authority
MA
Morocco
Prior art keywords
antibacterial agents
heterocyclic compounds
heterocyclic
antibacterial
compounds
Prior art date
Application number
MA045377A
Other languages
English (en)
Inventor
Jérôme Émile Georges Guillemont
Pierre Jean-Marie Bernard Raboisson
Abdellah Tahri
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA45377A publication Critical patent/MA45377A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045377A 2016-06-16 2017-06-15 Composés hétérocycliques en tant qu'agents antibacteriens MA45377A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16174719 2016-06-16

Publications (1)

Publication Number Publication Date
MA45377A true MA45377A (fr) 2019-04-24

Family

ID=56132837

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045377A MA45377A (fr) 2016-06-16 2017-06-15 Composés hétérocycliques en tant qu'agents antibacteriens

Country Status (12)

Country Link
US (1) US11179396B2 (fr)
EP (1) EP3472158A1 (fr)
JP (1) JP2019518046A (fr)
KR (1) KR20190017948A (fr)
CN (1) CN109476657A (fr)
AU (1) AU2017286368B2 (fr)
BR (1) BR112018076126A2 (fr)
CA (1) CA3026010A1 (fr)
EA (1) EA201990043A1 (fr)
MA (1) MA45377A (fr)
MX (1) MX2018015656A (fr)
WO (1) WO2017216281A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
WO2017049321A1 (fr) 2015-09-17 2017-03-23 Miller Marvin J Composés hétérocycliques contenant de la benzylamine et compositions utiles contre une infection mycobactérienne
EP3472158A1 (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Composés hétérocycliques en tant qu'agents antibacteriens
EP3589323B1 (fr) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Polythérapie pour le traitement de la tuberculose
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
EP3707135A1 (fr) 2017-11-06 2020-09-16 Jubilant Prodel LLC Dérivés de pyrimidine utilisés en tant qu'inhibiteurs de l'activation de pd1/pd-l1
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
EP3765453A1 (fr) 2018-03-13 2021-01-20 Jubilant Prodel LLC Composés bicycliques utilisés en tant qu'inhibiteurs de l'interaction/activation de pd1/pd-l1
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
MX2022003037A (es) 2019-09-13 2022-04-07 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
AU2020356630A1 (en) * 2019-09-26 2022-03-31 The Global Alliance For Tb Drug Development, Inc. Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections
CA3151712A1 (fr) 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Inhibiteurs de cytochrome bd comme agents antibacteriens pour le traitement de la tuberculose
AU2020358643A1 (en) 2019-09-30 2022-05-26 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
CN117396475A (zh) 2021-03-16 2024-01-12 爱尔兰詹森科学公司 抗菌化合物
MX2023010941A (es) * 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022214520A1 (fr) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Composés antibactériens
WO2022214519A1 (fr) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Composés antibactériens
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
WO2024089170A1 (fr) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Composés antibactériens
WO2024223859A1 (fr) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Composés antibactériens

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ295528A (en) 1994-11-15 1999-03-29 Upjohn Co Bicyclic oxazine and thiazine oxazolidinone antibacterials
ES2162047T3 (es) 1995-05-11 2001-12-16 Upjohn Co Oxazolidinonas con resto diazinilo y carbazinilo espirociclico y biciclico.
ES2343458T3 (es) 2002-07-25 2010-08-02 Janssen Pharmaceutica Nv Derivados de quinolina y su uso como inhibidores de micobacterias.
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CA2672960A1 (fr) 2006-12-20 2008-07-10 Schering Corporation Nouveaux inhibiteurs de jnk
TW200901969A (en) 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
JP5613656B2 (ja) 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
EP2353008A2 (fr) 2008-09-22 2011-08-10 Oregon Health and Science University Méthodes permettant de détecter une infection par le bacille de koch
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
RU2608611C2 (ru) 2009-11-05 2017-01-23 Юниверсити Оф Нотр Дам Дю Лак СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
ES2572387T3 (es) * 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
JP6134319B2 (ja) 2011-09-01 2017-05-24 ノバルティス アーゲー ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物
ES2620668T3 (es) 2012-03-02 2017-06-29 Genentech, Inc. Derivados de amidas y sulfonamidas amido espirocíclicas
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2014015167A2 (fr) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac Composés anti-infectieux 5,5-hétéroaromatiques
EA201590339A1 (ru) * 2012-08-10 2015-06-30 Янссен Сайенсиз Айрлэнд Юси Новые антибактериальные соединения
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
CN105745208A (zh) 2013-08-02 2016-07-06 韩国巴斯德研究所 一种抗感染化合物
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2016073524A1 (fr) 2014-11-03 2016-05-12 The Regents Of The University Of California Multithérapies médicamenteuses pour le traitement de la tuberculose
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
CA3025727A1 (fr) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Composes heterocycliques utilises en tant qu'agents antibacteriens
EP3472158A1 (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Composés hétérocycliques en tant qu'agents antibacteriens
EP3589323B1 (fr) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Polythérapie pour le traitement de la tuberculose

Also Published As

Publication number Publication date
JP2019518046A (ja) 2019-06-27
MX2018015656A (es) 2019-03-14
BR112018076126A2 (pt) 2019-03-26
AU2017286368A1 (en) 2018-12-06
EA201990043A1 (ru) 2019-05-31
AU2017286368B2 (en) 2021-02-25
CA3026010A1 (fr) 2017-12-21
US11179396B2 (en) 2021-11-23
EP3472158A1 (fr) 2019-04-24
US20190134046A1 (en) 2019-05-09
CN109476657A (zh) 2019-03-15
KR20190017948A (ko) 2019-02-20
WO2017216281A1 (fr) 2017-12-21

Similar Documents

Publication Publication Date Title
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
EP3533787A4 (fr) Composé de pyridone en tant qu'inhibiteur de c-met
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EP3621624A4 (fr) Composés dinucléotidiques cycliques en tant qu'agonistes sting
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
EP3883570A4 (fr) Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EP2989106A4 (fr) Composés hétérocycliques fusionnés en tant qu'inhibiteurs de protéine kinase